Artificial intelligence (AI) is the emulation of human intellectual processes by computer systems, such as learning, reasoning, problem solving, and decision making[1]. In the healthcare sector, AI has emerged as a transformational tool, notably in clinical trials. Clinical trials are critical for determining the safety and efficacy of novel medications and medical equipment. However, traditional clinical trial processes are frequently complex, time-consuming, costly, and prone to operational inefficiencies[2].

AI technologies, including machine learning (ML), deep learning, natural language processing (NLP), and predictive analytics, are increasingly being used in various stages of clinical trials. These tools allow researchers to analyse massive amounts of structured and unstructured data, such as electronic health records (EHRs), genomic data, imaging data, and real-world evidence. AI can use advanced algorithms to more efficiently identify eligible participants, refine study designs, forecast patient outcomes, and improve data monitoring processes.

AI technology has made substantial contributions to clinical trials by improving patient recruitment and retention, which are two of the most common causes of trial delays. AI-powered systems can quickly screen potential participants based on eligibility requirements and estimate dropout risks[3]. Additionally, AI supports adaptive trial designs, real-time safety monitoring, and decentralised clinical trials through wearable devices and remote patient monitoring technologies.

Despite its high promise, implementing AI in clinical trials necessitates careful consideration of data protection, regulatory compliance, ethical standards, and algorithm openness. As regulatory authorities and research institutions attempt to build frameworks for AI validation and governance, AI is likely to play an increasingly important role in speeding up drug development and enhancing clinical research outcomes.

To summarise, artificial intelligence is a strong tool that improves clinical trial efficiency, precision, and innovation, opening the way for more personalised and data-driven healthcare solutions.

AI in clinical trials aims to improve efficiency, accuracy, safety, and cost-effectiveness. The main objectives are listed below:

Improve patient recruitment and selection[4]

Optimise clinical trial design

Enhance Data Collection and Management

Improve patient monitoring and safety

Reduce the time and cost of drug development

Support regulatory compliance and reporting[5]

Enable personalised and precise medicine

Clinical trial guidelines are regulations that govern the ethical conduct, safety, and scientific validity of human clinical research. These standards apply globally to testing novel medications, vaccines, and medical devices. 

The most generally accepted global guidelines are: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).It Provides ICH-GCP (Good Clinical Practice) recommendations. Ensures trial participant safety and data dependability.

ICH-GCP Guidelines include:

ICHE6-GCP: In order to ensure ongoing relevance in the face of continuous technological and methodological improvements, ICH E6 incorporates novel requirements intended to apply across a variety of clinical trial types and situations[7]. This guideline offers a new vocabulary to support technological, operational, and clinical trial design advancements. Fit-for-purpose solutions are promoted by encouraging a risk-based and balanced approach to clinical studies. Through clinical trial registration and result reporting, it promotes transparency and provides more assistance to improve the informed consent procedure.

ICHE6(R3)[8]: The ICH E6 Good Clinical Practice (GCP) Guideline has a major influence on patients and trial participants and is extensively used by clinical trial researchers outside of ICH's membership and regional representation. The ICH Management Committee is making available a draft, work-in-progress version of the revised principles that are presently being developed by the ICH E6(R3) Expert Working Group (EWG) in recognition of the extensive and significant impact of ICH E6. To ensure ethical trial conduct, participant safety, and trustworthy clinical trial outcomes, the interdependent principles should be taken into account as a whole.

ICHE8: The goal of our in-depth course on ICH guideline E8 (R1) General Considerations for Clinical Studies is to provide you with a thorough understanding of the most recent guidelines for clinical research studies. This course covers every crucial component of the International Council for Harmonisation's (ICH) E8 guideline, which offers a thorough framework for the planning, execution, analysis, and reporting of clinical investigations[9]. Throughout the course, you will learn about the internationally recognised principles and practices in the design and conduct of clinical studies that will facilitate data acceptance, as well as the revised main concepts and principles of ICH (E8).

ICHE3[10]: This International Conference on Harmonisation (ICH) document makes recommendations on information that should be included in a core clinical study report of an individual study of any therapeutic, prophylactic, or diagnostic agent conducted in human subjects. The guideline is intended to assist sponsors in the development of a report that is complete, free from ambiguity, well-organised and easy to review.

There are typically four stages to clinical trials[11]:

1. Phase Objective

Phase I: Test dose and safety in a small group of 20–100 individuals

Phase II: Assess side effects and efficacy

Phase III: Verify efficacy in sizable populations

Phase IV: Safety monitoring after marketing

2. Moral Principles

The sources of ethical values are:

3. Authorities in Charge[12]

Clinical trials are regulated by agencies in many countries:

These organisations examine trial data, oversee safety, and authorise studies.

4. Important Clinical Trial Documents

Important records consist of: 

United States (USA):

Europe (EU):

India:

United Kingdom (UK):

Japan:

Australia:

nQuery

Panacea

TrialMatchAI

Oracle Clinical

1000minds

Deep 6 AI: Deep 6 AI uses artificial intelligence to scan electronic health records (EHRs) and quickly identify eligible patients for clinical trials, significantly reducing the time required for recruitment.

IBM Watson for Clinical Trial Matching: This tool applies natural language processing (NLP) to analyze patient medical records and match them with suitable clinical trials, improving accuracy in patient selection.

TriNetX: TriNetX leverages real-world patient data from hospitals and healthcare organizations to identify and recruit potential participants for clinical trials.

Antidote: Antidote is an AI-powered platform that connects patients with appropriate clinical trials based on their health data, making it easier for patients to find relevant studies.

Mendel.ai: Mendel.ai extracts and structures clinical information from medical records to efficiently identify eligible participants for clinical trials.

Medidata Rave: Medidata Rave uses artificial intelligence and advanced analytics to support remote monitoring, risk-based monitoring, and real-time tracking of clinical trial data, helping ensure data quality and faster decision-making.

CluePoints: CluePoints applies statistical algorithms and AI to detect data anomalies, inconsistencies, and protocol deviations, improving the reliability and integrity of clinical trial data.

IBM Watson Health: IBM Watson Health analyzes clinical trial data to monitor patient safety and predict potential adverse events, enabling proactive risk management.

Saama Life Science Analytics Cloud: This platform provides AI-driven clinical data monitoring and automated quality checks, ensuring accuracy and compliance throughout the trial process.

Veeva Vault Clinical: Veeva Vault Clinical supports trial monitoring, document management, and regulatory compliance, streamlining clinical operations and improving oversight.

Preparation of the Protocol → Ethics Committee Approval → CDSCO Submission → DCGI Review → CTRI Registration → Trial Commencement → Safety Monitoring

1. Insilico Medicine – AI-Designed Drug (Rentosertib)

AI role

Results

Significance

2. Deep 6 AI – Patient Recruitment for Clinical Trials

AI role

Results

Significance

The future outlook for regulatory affairs is centred on how globalisation, new technologies, and quicker medication development may alter regulatory procedures in the years to come. Regulatory experts will be crucial in maintaining the safety, efficacy, and compliance of pharmaceuticals and medical devices with international standards.

a. Automation and Artificial Intelligence

b. Submissions for Digital Regulation

d. International Regulation Harmonisation. Advanced Therapies and Personalised Medicine

e. Empirical Data (RWE)

Simulation-Based Methodology

Simulation-based methodology involves the use of computational tools to replicate clinical trial scenarios and optimize outcomes before actual implementation.

1. Data Collection and Categorization

Data was collected and categorized 

2. Data Entry and Processing

3. Eligibility Criteria Simulation

A rule-based formula was applied

=IF(AND(A2>40, LOWER(B2)=” HIGH”, LOWER(C2)=” YES”),” ELIGIBLE”,”  NOT ELIGIBLE”)

Based on the formula, the eligibility criterion differentiates:

Criteria Applied:

Outcome

Simulation Outcome

Significance of Simulation

AI is revolutionising the planning, execution, and evaluation of clinical studies. AI enhances clinical research efficiency, accuracy, and decision-making through cutting-edge technologies such as machine learning, deep learning, and natural language processing. Faster patient recruitment, better clinical trial design, enhanced data analysis, and early adverse event detection are all made possible by AI. These features improve patient safety and trial success rates while cutting down on the time and expense needed for drug development. AI also aids in the creation and analysis of data for regulatory organisations, including the Central Drugs Standard Control Organisation, the European Medicines Agency, and the Food and Drug Administration.